N/A
Manufactured by Tonix Medicines, Inc.
47,922 FDA adverse event reports analyzed
Last updated: 2026-04-14
SUMATRIPTAN SUCCINATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Tonix Medicines, Inc.. The most commonly reported adverse reactions for SUMATRIPTAN SUCCINATE include DRUG INEFFECTIVE, HEADACHE, MIGRAINE, NAUSEA, FATIGUE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for SUMATRIPTAN SUCCINATE.
Out of 23,879 classified reports for SUMATRIPTAN SUCCINATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 47,922 FDA FAERS reports that mention SUMATRIPTAN SUCCINATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, HEADACHE, MIGRAINE, NAUSEA, FATIGUE, PAIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Tonix Medicines, Inc. in connection with SUMATRIPTAN SUCCINATE. Always verify the specific product and NDC with your pharmacist.